Efficacy and safety of uro-vaxom treatment for patients with recurrent cystitis: An open multicenter studyopen access
- Authors
- Lee S.-J.; Kim S.J.; Cho Y.-H.; Woo Y.N.; Kim B.W.; Chang S.G.; Kim M.E.; Kim C.S.; Lee J.G.; Sim B.S.; Kim H.J.; Chung B.H.; Cho I.R.; Lee S.D.
- Issue Date
- 2007
- Publisher
- Korean Urological Association
- Keywords
- Cystitis; Escherichia coli; Female; Uro-Vaxom
- Citation
- Korean Journal of Urology, v.48, no.4, pp 428 - 432
- Pages
- 5
- Indexed
- SCOPUS
- Journal Title
- Korean Journal of Urology
- Volume
- 48
- Number
- 4
- Start Page
- 428
- End Page
- 432
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/31787
- DOI
- 10.4111/kju.2007.48.4.428
- ISSN
- 0494-4747
- Abstract
- Purpose: We wanted to investigate the efficacy and safety of the immunotherapeutic Uro-Vaxom for treating uncomplicated recurrent cystitis in female patients only. Materials and Methods: Adult female patients were enrolled in this multicenter, open-label study if they had acute cystitis at the enrollment visit and positive results on urine culture (≥103 CFU/ml). The patients were treated for 3 months with one capsule daily of Uro-Vaxom after antibiotic therapy, and they were observed for another 3 months. The primary efficacy criteria were the cystitis recurrence rates over 6 months, the distribution of cystitis and the proportion of patients with cystitis. Results: A total of 50 patients were evaluated. During the 6-month trial, the number of cystitis recurrences was significantly reduced in comparison with the 6-month pretrial period (on the average 0.64 as compared to 3.0 recurrences, respectively p < 0.001). The incidences of frequency, urgency and dysuria remained low until the end of the trial. Uro-Vaxom was well tolerated: side-effects were mentioned by 8% of the 50 patients, and there was no case leading to treatment withdrawal. Conclusions: Uro-Vaxom significantly reduced the incidence of cystitis during the 6 months of this study, including the 3 months of treatment. These results demonstrate that Uro-Vaxom is a valuable agent for prophylaxis of recurrent cystitis.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Urology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.